Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China - Concepedia

Concepedia

Publication | Open Access

Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China

DOI Full Paper Access

37

Citations

18

References

2022

Year

Changying Shi, Yulong Li, Cheng‐Ta Yang, Liang Qiao, Liukang Tang, Yuting Zheng, Xue Chen, You‐Wen Qian, Jiamei Yang, Dong Wu,

Frontiers in Immunology

Abstract

Lenvatinib plus PD-1 antibody treatment shows an active trend towards improving survival in patients with advanced BTCs after failure with CisGem chemotherapy. The treatment-related AEs are worthy of attention and are manageable.

References

	Year	Citations

Page 1